Table I.

Details of patients with palmoplantar keratoderma treated with apremilast

Patient	Age/Sex	Systemic disease	Diagnosis	Prior treatment	Concomitant therapy	Effect of apremilast	Period needed, months
Case 1	60s/F	None	Psoriasis vulgaris	Topical corticosteroids and vitamin D3 analogues	Topical corticosteroids and vitamin D3 analogues	Excellent	2
Case 2	50s/F	None	Psoriasis vulgaris	Topical corticosteroids, NB-UVB, etretinate	Topical corticosteroids	Good	3
Case 3	40s/F	None	Psoriasis vulgaris	Topical corticosteroids, NB-UVB, cyclosporine	Topical corticosteroids and vitamin D3 analogues	Excellent	2
Case 4	30s/F	Hypothyroidism	Pityriasis rubra pilaris	Topical vitamin D3 analogues	Topical corticosteroids and moisturizer	Mild	3
Case 5	40s/M	Hyperuricaemia, dyslipidaemia and diabetes mellitus	Congenital ichthyosiform erythroderma	Topical corticosteroids and vitamin D3 analogues, etretinate	Topical corticosteroids and vitamin D3 analogues, etretinate	Mild	4
Case 6	60s/M	None	Acquired PPK	Topical corticosteroids, urea- and salicylic acid-containing ointments, etretinate	Topical corticosteroids and vitamin D3 analogues	Excellent	2

NB-UVB: narrow-band ultraviolet B; PPK: palmoplantar keratoderma.